In a recent article, I discussed the rise of targeted protein degradation (TPD) therapeutics and the surge in big pharma interest in this emerging space. With more than 3,600 tweets posted over the last three years to over 5,000 articles published over the last decade, the concept of targeted protein degradation has got the right people talking.
In contrast to the traditional small molecule inhibitors and antibody drugs, protein degraders are designed to develop drug candidates for many intractable diseases that other therapeutic modalities cannot address.
To say that this space is growing would be an understatement. The potential to drug the undruggable is just far too more lucrative to let a few roadblocks come in the way. Here is a look at some of the key growth drivers and roadblocks in the targeted protein degradation space: